Market Overview

Jefferies Reiterates Buy Rating, $36 PT on Incyte Corporation Despite PML Case

Share:
Related INCY
Mark Your Calendar For These Days In May To Play The Volatility Around FDA Decision Dates
Earnings: Caterpillar, Lockheed Martin, and Eli Lilly Report Tomorrow
Braun Stacey Associates Inc Buys Incyte, KB Home, Pinnacle Foods, Sells Vulcan Materials Co, ... (GuruFocus)

In a report published Monday, Jefferies analyst Thomas Wei reiterated a Buy rating and $36.00 price target on Incyte Corporation (NASDAQ: INCY).

In the report, Wei noted, “INCY today disclosed a 75-year old male patient developed PML, a rare brain infection, while taking Jakafi. We still believe that the overall risk-benefit profile of Jakafi is favorable and note that the causal relationship between Jakafi and the PML case is unclear with spontaneous reports of PML in the myelofibrosis literature, and there has been a favorable trend on overall survival seen in the Phase 3 trials.”

Incyte Corporation closed on Friday at $24.84.

Latest Ratings for INCY

DateFirmActionFromTo
Apr 2017PiperJaffrayDowngradesOverweightNeutral
Apr 2017Gabelli & Co.Initiates Coverage OnBuy
Apr 2017Raymond JamesDowngradesOutperformMarket Perform

View More Analyst Ratings for INCY
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Reiteration Analyst Ratings

 

Related Articles (INCY)

View Comments and Join the Discussion!